Loading clinical trials...
Loading clinical trials...
A Randomised, Double-blind, Double Dummy, 3 Way Cross-over Study Evaluating the Effects of ADOAIR 50/250mcg Twice Daily Plus Tiotropium Bromide 18mcg Once Daily Compared With the Individual Treatments (Tiotropium Bromide 18mcg Alone and ADOAIR 50/250mcg Alone) in the Treatment of Japanese Subjects With COPD
Conditions
Interventions
fluticasone propionate/salmeterol
tiotropium bromide
+1 more
Locations
3
Japan
GSK Investigational Site
Hokkaido, Japan
GSK Investigational Site
Ibaraki, Japan
GSK Investigational Site
Osaka, Japan
Start Date
February 1, 2013
Primary Completion Date
November 1, 2013
Completion Date
November 1, 2013
Last Updated
March 8, 2017
NCT06831994
NCT02755974
NCT05050591
NCT05913765
NCT05592847
NCT00683722
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions